Pregliasco, 1-2% reinfections after vaccination but not serious

(ANSA) - ROME, JUN 15 - Cases of reinfection by SarsCov2 have also been reported in Italy despite vaccination.

The virologist Fabrizio Pregliasc of the University of Milan, despite the lack of official data that is statistically relevant at the moment: "According to estimates in our vaccination center at the Galeazzi Institute in Milan - he says to ANSA - we found a percentage equal to 1- 2% reinfection after the second dose of anti-Covid Pfizer vaccine. These are non-serious forms ".

    In these cases, explains the expert, "we observed that this is a much weaker and uncomplicated reinfection, and in most cases due to the Alpha variant, previously called the English variant. The reinfection was detected after 1-2 months after completion of the cycle vaccination ". In recent days, moreover, "a case of post-vaccine reinfection from the Delta (Indian) variant was also detected in Lombardy. The positive data - he underlines - is that in any case the infections are mild, therefore this indicates an efficacy of the vaccine in mitigating the impact of reinfection itself ". According to Pregliasco, this data therefore demonstrates that "despite the possible margin of reinfection, the vaccine is effective and the objective is in any case to avoid serious illness.

   Even with respect to the Delta variant - he notes - studies tell us that in 80% of cases hospitalizations and cases of pregnancy are avoided after the single dose and in 95% of cases after the two doses, according to English data. The conclusion, the virologist comments, is that the "vaccine is needed, even considering this partial ineffectiveness with respect to some reinfections, and this to reduce what may be the future tail blow in light of the possible onset and spread in Italy, very likely, of the Delta variant. . And this is because the vaccine is the only possibility to prevent a heavy impact from a clinical point of view on hospital structures. The important thing, from a public health point of view, is, in fact, first of all to avoid serious cases ". Compared to the variants, he concludes, "however, a third vaccination with updated vaccines against mutations is now essential, to be carried out by 2022 ".

   (HANDLE).